[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,209,365
  • Shares Outstanding, K 310,985
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,550 K
  • EBIT $ -293 M
  • EBITDA $ -295 M
  • 60-Month Beta 0.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.12

Options Overview Details

View History
  • Implied Volatility 91.28% (+12.17%)
  • Historical Volatility 211.81%
  • IV Percentile 3%
  • IV Rank 3.32%
  • IV High 445.66% on 05/23/25
  • IV Low 79.11% on 05/19/26
  • Expected Move (DTE 29) 2.12 (19.07%)
  • Put/Call Vol Ratio 3.28
  • Today's Volume 719
  • Volume Avg (30-Day) 5,438
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 97,385
  • Open Int (30-Day) 125,336
  • Expected Range 8.98 to 13.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 6
  • High Estimate $-0.11
  • Low Estimate $-0.13
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.70 +29.71%
on 04/28/26
24.28 -53.52%
on 04/23/26
-10.42 (-48.02%)
since 04/20/26
3-Month
8.70 +29.71%
on 04/28/26
24.28 -53.52%
on 04/23/26
-1.26 (-10.01%)
since 02/20/26
52-Week
1.06 +964.62%
on 05/27/25
24.28 -53.52%
on 04/23/26
+10.01 (+781.64%)
since 05/20/25

Most Recent Stories

More News
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members...

ERAS : 11.31 (+9.59%)
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference

Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal...

ERAS : 11.31 (+9.59%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact...

ERAS : 11.31 (+9.59%)
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company...

ERAS : 11.31 (+9.59%)
Erasca's Pan-RAS Molecule Either Validates Years of Losses Tomorrow or Resets the Clock

Barchart Research What to Expect from ERAS Earnings ERAS Generated May 11, 2026 Current Price $10.44 EPS Estimate $$-0.19 Consensus Rating Moderate Buy Average Move 5.08% Erasca's Pan-RAS Molecule Either...

ERAS : 11.31 (+9.59%)
Erasca Reports First Quarter 2026 Business Updates and Financial Results

Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted...

ERAS : 11.31 (+9.59%)
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients...

ERAS : 11.31 (+9.59%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS).  Such investors are advised to contact...

ERAS : 11.31 (+9.59%)
Erasca to Present at the Bank of America Securities Health Care Conference

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients...

ERAS : 11.31 (+9.59%)
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L...

ERAS : 11.31 (+9.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 11.42
2nd Resistance Point 11.10
1st Resistance Point 10.71
Last Price 11.31
1st Support Level 10.00
2nd Support Level 9.68
3rd Support Level 9.29

See More

52-Week High 24.28
Fibonacci 61.8% 15.41
Fibonacci 50% 12.67
Last Price 11.31
Fibonacci 38.2% 9.93
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.